基于 2 个已确定 T+90 收益的买入信号。收益基准:公布次日的收盘价。
Discover the complete record of transactions filed by Yasha MITROTTI, Executive Vice President, Industrial Applications. Director active across 1 company, notably BIOMERIEUX. Aggregated, 2 disclosures have been recorded. Split: 2 buys · 0 sell. Total volume traded: €38k. Activity tracked since 23 June 2023. The latest transaction was filed on 27 June 2025 (Acquisition). Regulator: AMF. All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 条申报中的 2 条
Yasha Mitrotti serves at bioMérieux as Executive Vice President, Industrial Applications and is a member of the company’s executive leadership team. In that role, he is responsible for a strategic business area that covers industrial microbiology and application-driven solutions for demanding sectors such as food safety, biopharmaceutical manufacturing, and regulated production environments. bioMérieux’s governance pages list him among the core executive committee members, underscoring the seniority and operational importance of his mandate. His remit is closely tied to innovation, industrial performance, and the commercialization of technologies that help customers improve quality control and reduce contamination risks. Public bioMérieux communications frequently feature him in connection with product launches and strategic partnerships, particularly in food safety and industrial microbiology. He has spoken about initiatives with Mérieux NutriSciences and major food-industry players aimed at building a more collaborative, data-driven model for food safety, as well as the launch of GENE-UP® TYPER, a solution designed to help rapidly identify the root cause of Listeria monocytogenes contamination. Mitrotti’s expertise appears to span industrial microbiology, application development, and market execution in highly regulated environments. bioMérieux also linked him to the acquisition of Accellix, presented as a move to strengthen the company’s quality-control portfolio for cell and gene therapies by adding cell purity and viability capabilities. That transaction illustrates a broader strategic focus on expanding the company’s industrial applications platform into fast-growing life-science segments. Overall, Yasha Mitrotti can be characterized as a senior industrial leader focused on translating scientific expertise into scalable customer solutions. His role in the executive committee places him at the center of bioMérieux’s strategic priorities, where he contributes to growth, product innovation, and the reinforcement of quality standards across industrial markets.